Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261
info@rgenix.com

Patients

Developing new cancer therapies and improving the quality of patients’ lives is at the heart of everything we do. By focusing on novel first-in-class drug development, we aim to develop the therapies of the future. Our goal is to create effective therapies that provide meaningful and durable benefit to cancer patients.

Actively Recruiting Patients

Clinical trials are an essential part of discovering new cancer therapies and making them available to those in need. We are actively seeking patient volunteers for the following clinical trials:

Clinical Trial

RGX-104

This study evaluates the efficacy of RGX-104, a novel oral small molecule immunotherapy candidate, in combination with other agents. Patients diagnosed with a wide range of conditions, including the following, may be eligible to participate in our clinical trial:

Non-Small Cell Lung Cancer
Small Cell Lung Carcinoma
High-grade Neuroendocrine
Clinical Trial

RGX-202

This study is designed to evaluate the therapeutic effect of oral RGX-202 administration as a single agent or combination therapy in patients with advanced gastrointestinal tumors. Patients diagnosed with any of the following malignant gastrointestinal tumors may be eligible to participate:

Colorectal
Gastric
Gastroesophageal Junction

About RGX-104

About RGX-202

RGX-104 is an investigational small molecule immunotherapy that activates LXR, resulting in depletion of both myeloid-derived suppressor cells (MDSCs) as well as tumor blood vessels. MDSCs block the ability of T-cells and other cells of the immune system to attack tumors.

RGX-202 is a small molecule that suppresses gastrointestinal cancer growth by inhibiting a novel cancer metabolism pathway involved in supplying energy to cancer cells.